Multivalent Coronavirus Carriers for Broad Neutralizing Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing vaccines provide limited protection against emerging coronaviruses, particularly those originating from zoonotic sources, necessitating a vaccine that induces broad-spectrum neutralizing responses against multiple coronaviruses, including SARS-CoV-2 and related strains.
Innovation Solution
A multivalent carrier-based vaccine composition displaying a plurality of coronavirus antigens, including RBDs from different coronaviruses, is administered to stimulate cross-reactive immune responses, using nanoparticles like Ap205 VLPs or self-assembling nanoparticles, potentially with adjuvants, to induce neutralizing antibodies against diverse coronaviruses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a single-valent vaccine targets a specific coronavirus, then it provides strong protection against that particular virus, but it offers limited protection against emerging and zoonotic coronaviruses
Solution Approach 1:
The patent applies multivalency by incorporating multiple coronavirus antigens (including SARS-CoV-2, SARS-CoV, MERS-CoV, and zoonotic strains) onto a single nanoparticle carrier. This allows the vaccine to simultaneously target multiple coronavirus types, providing both broad protection across different strains and reliable immunity through conserved antigen presentation that elicits cross-reactive neutralizing antibodies.
2Adaptability or versatility
If natural infection induces immunity, then it provides protection against the infected virus, but it fails to achieve broad cross-protection against other coronaviruses
Solution Approach 1:
The patent merges multiple coronavirus antigens onto a single nanoparticle carrier, combining them in close proximity to enable simultaneous recognition by the immune system. This merging strategy generates diverse antibody responses against multiple virus types from a single vaccine administration, achieving the cross-reactive immunity that natural infection cannot provide.
3Adaptability or versatility
If a multivalent vaccine includes multiple coronavirus antigens, then it induces broad cross-reactive antibody responses, but it increases the complexity of the vaccine formulation
Solution Approach 1:
The patent applies local quality by strategically positioning different coronavirus antigens at specific locations on the nanoparticle surface. This spatial arrangement ensures that each antigen is properly displayed and accessible to the immune system while maintaining the overall structural integrity of the nanoparticle carrier, thus managing formulation complexity through organized antigen distribution.
4Adaptability or versatility
If the vaccine uses conserved antigen regions, then it can target multiple coronavirus strains, but it may reduce the immunogenicity compared to strain-specific antigens
Solution Approach 1:
The patent uses composite materials by combining multiple coronavirus antigens (including conserved regions like RBDs and spike proteins) with a nanoparticle carrier system. This composite approach maintains the immunogenicity of strain-specific antigens while incorporating conserved regions that enable cross-strain protection, achieving both strong immune response and broad versatility through synergistic antigen-carrier interactions.
Data Source
AI summary
Disclosed herein include multivalent carriers comprising a plurality of heterologous coronavirus proteins antigens derived from different coronaviruses. The multivalent carriers herein described can elicit heterologous binding and neutralization properties against coronaviruses that differ from the coronaviruses from which the coronavirus antigens are derived to produce the multivalent carriers. Also provided herein include vaccine compositions comprising the multivalent carriers and related methods using the vaccine compositions in various therapeutic and prophylactic applications.